Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
about
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancerNonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analogCharacterization of DNA topoisomerase I from Candida albicans as a target for drug discoveryCFS-1686 causes cell cycle arrest at intra-S phase by interference of interaction of topoisomerase 1 with DNAThe structure–activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding modeSynthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: Investigating the hypothesis of shared structure–activity relationshipsDNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial InhibitionSynthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen HeterocyclesEffective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood.A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.GilR, an unusual lactone-forming enzyme involved in gilvocarcin biosynthesis.Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sitesSynergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticlesYeast histone 2A serine 129 is essential for the efficient repair of checkpoint-blind DNA damageThe novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.Human topoisomerase I C-terminal domain fragment containing the active site tyrosine is a molten globule: implication for the formation of competent productive complex.Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.Preparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinoma-targeted drug deliveryKinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins.Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitorsCancer therapies utilizing the camptothecins: a review of the in vivo literatureThe synergism between Belotecan and cisplatin in gastric cancer.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.Topoisomerase I inhibitors and drug resistanceAn analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.Fabrication and optimization of camptothecin loaded Eudragit S 100 nanoparticles by Taguchi L4 orthogonal array design.The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?Current perspectives on camptothecins in cancer treatment
P2860
Q24648015-A068447B-A2BD-4EB5-B52B-184E537E7730Q27639935-FF310FF2-2738-4E50-A48D-3F169CC20DD0Q28327002-1FC690A3-A057-4520-A288-7642D92BA205Q28542408-EFB8A092-9623-41BB-A940-E1FB174AE881Q29028715-BE1AB58E-5981-417A-A05A-5DDCA6FEC382Q29038255-3B24BAB8-19BD-4449-9282-A731B89A843BQ29400901-538C9AFA-2511-41D9-8A5D-7025AA72E725Q29544329-E912874B-6532-4E67-BA67-D44BBD19C01CQ30667530-9F9D6E6B-E707-49A0-85F2-4CC4B8D45312Q33374599-03638258-FC94-41FB-BBE1-D0D4D68D4E86Q33662415-00A42132-C5AF-47FF-8154-BC23F52CF544Q33696187-7AF1ECE5-E49A-4760-833C-779997E0695AQ33812633-5A0976DB-F01B-4724-B644-26BF718F0E4AQ33888541-42039757-8FE8-4C47-A2C2-E30D37B07A1DQ33932878-ABFE67FF-85EE-49A7-9E80-82CD2ABC86C9Q34028831-8FB8DBBC-A414-4D25-B625-81BC16CE6550Q34250284-6B254562-28AF-4BC0-AFF5-AB151BCF2261Q34928276-3B07FCD5-CFE2-4148-8209-9C2BF892B9FAQ35076861-EB728C48-83E0-4BE9-8EDB-D19D88873444Q35152039-805DA08B-1B67-438E-B0F0-A2A1D652F36CQ36012501-651F2B39-19F5-40FC-8C08-BC759F347227Q36431807-00892989-C9E8-4995-B464-8A59492A6E12Q36617921-02F5292D-6641-4C2B-9C36-523A366137C3Q36695803-31650F98-4538-4B33-BC3E-D089BE305704Q36738734-69BF7084-4780-47C3-AB56-673270BDBC48Q36838603-CFF6EF3D-8A1A-4495-B70E-A1A5AB72E378Q36844392-F51D04C1-7CA3-4322-9BD4-DA116CFE2A29Q36853889-AE496C8B-690D-4C95-A9FA-47847E096752Q36882373-D9A31700-1415-4E9D-8DDE-C7BA0D47C70DQ37069556-0AA6776B-4D69-4040-80A9-26284C7068BCQ37341744-F547DB68-3F66-47B5-A398-F5E449B131B4Q37441604-441AC371-A9BF-4BDE-AFFD-DC4490453FB9Q37652515-2161776A-F646-4757-9FD4-92A41ACE917FQ37729428-C7A65DD6-1DC1-498D-8629-8E8935F63FEFQ40028536-5F71F81A-DC5C-4AC0-AB24-BD5B9DEF17EFQ40459351-AD9D80C3-49C4-4263-BABA-3F8AFFC1B684Q40642201-7E51112F-0EAA-4988-B84E-923CB0491309Q41723159-7CC2CED5-739B-4ECF-9466-EED3025E6B2EQ42318574-76644A86-42DC-4ABB-A57E-C99C7A066D99Q42715927-3E507BB3-5DC6-497F-9455-43E6A0FB75AA
P2860
Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Structure-activity study of th ...... elation to antitumor activity.
@en
Structure-activity study of th ...... elation to antitumor activity.
@nl
type
label
Structure-activity study of th ...... elation to antitumor activity.
@en
Structure-activity study of th ...... elation to antitumor activity.
@nl
prefLabel
Structure-activity study of th ...... elation to antitumor activity.
@en
Structure-activity study of th ...... elation to antitumor activity.
@nl
P2093
P1433
P1476
Structure-activity study of th ...... relation to antitumor activity
@en
P2093
P304
P407
P577
1989-03-01T00:00:00Z